Blocking PCNA interaction with NKp44 enhances primary natural killer cell-mediated lysis of triple-negative breast cancer cells

被引:1
作者
Marrufo, Armando M. [1 ,2 ]
Mathew, Stephen O. [1 ]
Chaudhary, Pankaj [1 ]
Malaer, Joseph D. [1 ]
Ahmed, Nourhan [1 ]
Vishwanatha, Jamboor K. [1 ]
Mathew, Porunelloor A. [1 ]
机构
[1] Univ North Texas, Dept Microbiol Immunol & Genet, Hlth Sci Ctr, Ft Worth, TX 76107 USA
[2] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA
基金
美国国家卫生研究院;
关键词
PCNA; triple-negative breast cancer (TNBC); natural killer cells; NKp44; PCNA-NKp44; interaction; MOLONEY LEUKEMIA-CELLS; NUCLEAR ANTIGEN; CYTOTOXIC-CELLS; NK CELLS; SPECIFICITY; ACTIVATION; MOUSE; LLT1;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Among the innate immune cells, natural killer cells (NK) serve its role in cytolytic targeting against infected and cancerous cells. NK function is regulated by an intricate balance of signals from interactions between activating and inhibitory NK receptors and ligands expressed on target cells. As an immune evasion strategy, cancer cells, particularly triple-negative breast cancer cells (TNBCs), express ligands that interact with NK receptors to inhibit NK cell cytolytic function. Our studies have revealed that Proliferating Cell Nuclear Antigen (PCNA), normally expressed in the nucleus with DNA replication and repair roles, was present on the cell surface of TNBC cell lines MDA-MB-231, -436, and -468. To elucidate the function of cell surface PCNA, we blocked PCNA on TNBCs with antibodies which both disrupted interaction with NKp44 and enhanced lysis by primary NK cells. Furthermore, a combinational antibody treatment of TNBCs with alpha-LLT1 and alpha-PCNA antibodies augments NK-mediated lysis. These results together suggest that cell surface PCNA on TNBCs enables evasion from cytolytic killing by NK cells. Blocking PCNA-NKp44 interaction with antibodies may potentially open an additional avenue in treatment of TNBCs.
引用
收藏
页码:1082 / 1090
页数:9
相关论文
共 32 条
[1]   Natural Killer Cells: Development, Maturation, and Clinical Utilization [J].
Abel, Alex M. ;
Yang, Chao ;
Thakar, Monica S. ;
Malarkannan, Subramaniam .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[2]   Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].
Albain, K. ;
Anderson, S. ;
Arriagada, R. ;
Barlow, W. ;
Bergh, J. ;
Bliss, J. ;
Buyse, M. ;
Cameron, D. ;
Carrasco, E. ;
Clarke, M. ;
Correa, C. ;
Coates, A. ;
Collins, R. ;
Costantino, J. ;
Cutter, D. ;
Cuzick, J. ;
Darby, S. ;
Davidson, N. ;
Davies, C. ;
Davies, K. ;
Delmestri, A. ;
Di Leo, A. ;
Dowsett, M. ;
Elphinstone, P. ;
Evans, V. ;
Ewertz, M. ;
Gelber, R. ;
Gettins, L. ;
Geyer, C. ;
Goldhirsch, A. ;
Godwin, J. ;
Gray, R. ;
Gregory, C. ;
Hayes, D. ;
Hill, C. ;
Ingle, J. ;
Jakesz, R. ;
James, S. ;
Kaufmann, M. ;
Kerr, A. ;
MacKinnon, E. ;
McGale, P. ;
McHugh, T. ;
Norton, L. ;
Ohashi, Y. ;
Paik, S. ;
Pan, H. C. ;
Perez, E. ;
Peto, R. ;
Piccart, M. .
LANCET, 2012, 379 (9814) :432-444
[3]   Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [J].
Bianchini, Giampaolo ;
Balko, Justin M. ;
Mayer, Ingrid A. ;
Sanders, Melinda E. ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) :674-690
[4]   NKP44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence [J].
Campbell, KS ;
Yusa, S ;
Kikuchi-Maki, A ;
Catina, TL .
JOURNAL OF IMMUNOLOGY, 2004, 172 (02) :899-906
[5]   NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily [J].
Cantoni, C ;
Bottino, C ;
Vitale, M ;
Pessino, A ;
Augugliaro, R ;
Malaspina, A ;
Parolini, S ;
Moretta, L ;
Moretta, A ;
Biassoni, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) :787-795
[6]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[7]   Triple-Negative Breast Cancer [J].
Foulkes, William D. ;
Smith, Ian E. ;
Reis-Filho, Jorge S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) :1938-1948
[8]   Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer [J].
Gregorio, Ana C. ;
Lacerda, Manuela ;
Figueiredo, Paulo ;
Simoes, Sergio ;
Dias, Sergio ;
Moreira, Joao Nuno .
PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (04) :701-716
[9]   Cancer drug resistance: an evolving paradigm [J].
Holohan, Caitriona ;
Van Schaeybroeck, Sandra ;
Longley, Daniel B. ;
Johnston, Patrick G. .
NATURE REVIEWS CANCER, 2013, 13 (10) :714-726
[10]   NKp44 and natural cytotoxicity receptors as damage-associated molecular pattern recognition receptors [J].
Horton, Nathan C. ;
Mathew, Porunelloor A. .
FRONTIERS IN IMMUNOLOGY, 2015, 6